VCANBIO CELL & GENE ENGINEERING CORP., LTD

VCANBIO CELL & GENE ENGINEERING CORP., LTD (hereinafter referred to as "VCANBIO") is an enterprise firstly investing biological resources storage projects in China and also the only domestic biosciences enterprise in the stock markets of Shanghai and Shenzhen developed by dual-core drive of "cell + gene" (stock code: 600645). It has the domestic advanced cell technology and the largest cell resource storage network with over 300,000 cell reserve volume.

The Company insists on the core strategy upon dual-core development of "cell + gene" with the major businesses covering various cell storage businesses of newborns and adults; adult gene detection for newborns, advanced gene sequencing equipment development, biochemical reagent R&D and production together with clinical testing business; anti-aging business characterized by cell and gene technology; new drug R&D and production mainly based on the development of gene, cell and small molecule drugs; anti-tumor biological treatment technology mainly based on immune cell storage and technology R&D; the life bank card construction with a new model of the Internet + Comprehensive Health, focusing on precise medical treatment based on clinical samples and big gene database of Chinese population, and integrating on-line and off-line sales and service promotion.

After 17-year operation, VCANBIO has developed into a domestic leading biosciences group, established 2 overseas subsidiary companies, namely VcanBio USA Co., Ltd. and VcanBio Center for Translational Biotechnology Corp. ,and spread the global strategic layout. Through the strategic layouts in such aspects as cell storage, gene detection, biological treatment technology, pharmacy and life big data, VCANBIO is creating a frontier, inclusive and innovative "Precision Medicine" platform to bring the latest technology, the first-class talents and the most potential companies and projects in this open and inclusive platform, so as to benefit and serve the public by the advanced science and technology achievements.

The core technological and managerial team has more than 20 PhD, many of which have aboard study or working experiences. Above 97% of the team has bachelor degree. VCANBIO has also invited several leading scientists and scholars as the consultants of the technology committee, including:

  • Sir Martin Evans, former chancellor of Cardiff University and the Nobel Prize Laureate in Physiology and Medicine in 2007
  • Prof. Massimo Dominici, President of International Society for Cellular Therapy
  • Prof. Wu Zuze, former chairman of Medical Science Academy of the PLA and Chinese Academy of Engineering Academician, known as “the founder of China stem cell therapy”
  • Prof. Pei Gang, President of Tongji University, Academician of Chinese Academy of Sciences, President of Chinese Society of Cell Biology, Chief Editor of Cell Researc
  • Prof. Pei Xuetao, Director of Institute of Blood Transplantation Medicine, Academy of Military Medical Sciences
  • Prof. Xu Guotong, Vice President of Tongji Medical School, Tongji University
  • Prof. Yu Jun, one of Founders of BGI, Former deputy president of Beijing Institute of Genomics, Chinese Academy of Science

The Main Licenses or Certificates of VCANBIO:

  • National Stem Cell Engineering Industrialized Base issued by China State Planning Commission since 2000
  • National Research Center of Stem Cell Engineering issued by Chinese Ministry of Science and Technology since 2002
  • National Cell Product Engineering Research Center issued by China Development & Reform Commission since 2004
  • The deputy director of the National Strategic Alliance for Technical Innovation of Stem Cell and Regenerative Medicine Industry
  • The Practice License of Cord Blood Bank issued by Chinese Ministry of Health since 2001
  • The Practice License of Cord Blood Bank issued by Chinese Ministry of Health since 2001
  • Academician Workstation issued by China Association for Science and Technology since 2012
  • Postdoc Research Station issued by Chinese Ministry of Human Resources since 2002
  • National Level Gene Detection Technique Platform

Zhongyuan Union Cell & Gene Engineering Corp., Ltd.

Zhongyuan Union Cell & Gene Engineering Corporation, Ltd (Zhongyuan Union) is a leading and the only company focusing on cell and gene engineering technology in China, which is listed in the domestic stock market with code 600645. The company is one of the first companies investing biological resources storage and now dual drive by both cell and gene. Zhongyuan Union is also the deputy director of the National Strategic Alliance for Technical Innovation of Stem Cell and Regenerative Medicine Industry and has carried the project in building the national stem cell and gene clinical translational base. Meanwhile, it operates the Tianjin Cord Blood Bank, one of the large cord blood banks in the world.

After fifteen year successful development, Zhongyuan Union has operated four well-known affiliated companies, including Union Stem Cell & Gene Engineering Co., Ltd., Alliancells Bioscience Co., Ltd., Zhongyuan Union Gene Technology Co., Ltd and Shanghai Zhicheng Biological Technology Co., Ltd. At present, the Company owns biotech labs with more than 4000 square meters and its GMP standard production facilities. It has set up branch companies covering 23 provinces in China, provides the whole industrial chain products and services in cell and gene engineering. Its market value reaches 23 billion RMB.

The core technological and managerial team has more than 20 PhD and over 100 masters. Above 97% of the team has bachelor degree. Zhongyuan Union has also invited several world top scientists and scholars as the consultants of the technology committee, including:
‒ Sir Martin Evans, former chancellor of Cardiff University and the Nobel Prize Laureate in Physiology and Medicine in 2007
‒ Dr. Massimo Dominici, President of International Society for Cellular Therapy
‒ Prof. Wu Zuze, former chairman of Medical Science Academy of the PLA and Chinese Academy of Engineering Academician, known as “the founder of China stem cell therapy”
‒ Prof. Pei Gang, President of Tongji University, Academician of Chinese Academy of Sciences, President of Chinese Society of Cell Biology, Chief Editor of Cell Research
‒ Prof. Pei Xuetao, Director of Institute of Blood Transplantation Medicine, Academy of Military Medical Sciences
‒ Prof. Yu Jun, one of Founders of BGI, Former deputy president of Beijing Institute of Genomics, Chinese Academy of Science
‒ Prof. Xia Wenle, Director of Oncology Research Laboratory, Duke University Medical Center

The main advantages of the Zhongyuan Union:
 National Stem Cell Engineering Industrialized Base issued by China State Planning Commission since 2000
 National Research Center of Stem Cell Engineering issued by Chinese Ministry of Science and Technology since 2002
 National Cell Product Engineering Research Center issued by China Development & Reform Commission since 2004
 The deputy director of the National Strategic Alliance for Technical Innovation of Stem Cell and Regenerative Medicine Industry
 National Level Gene Detection Technique Platform
 The Consultant Team led by Nobel Prize Winners
 More than 90 national patents
 Undertaking many projects funded by "863 plan", "973 plan" and National Natural Science Foundation of China
 Cooperating with more than 80 3A-level domestic hospitals for the research on cell therapy for live diseases, neurological damages, immune system diseases and myocardial ischemia
 One of the largest cord blood banks with more than 300000 cord blood samples in storage

The main business of Zhongyuan Union:
 Cell banking (stem cell banking & immune cell banking)
 Gene testing & clinical diagnosis reagent
 Anti-aging products (makeup, healthcare product, )
 Tumor biotherapy
 Life bank service
 Zhongyuan Pharmacology
 Fund (M&A fund, public welfare fund for biological treatment, Venture capital fund)